NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Scilex Holding Company (SCLX) Stock Analysis

Scilex Holding Company (SCLX) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

SCLX

$5.42

+$0.13 (+2.56%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCLX with… →

SCLX Key Statistics

As of Sep 4, 2026
Trading
Open
$5.41
Previous Close
$5.28
Day's Range
5.29–5.72
52-Week Range
2.62–21.34
Volume
40.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.72
Valuation
Market Cap
$38.09M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
7.42
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.21
EPS (ttm)Profit attributable to each share over the last twelve months.
−50.20
Financials (FY)
Revenue (FY)
$30.25M−46.54%
Net Income (FY)
−$358.73M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.03M
1-Year Return
−57.33%
Dividend and dates
Avg Volume
116.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SCLX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.72%
2025−18.18%
2024−79.12%
2023−48.87%
2022−60.26%
2021 (partial year)+1.93%

As of September 4, 2026.

SCLX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$30.25M−$358.73M−1185.8%
2024$56.59M−$72.81M−128.7%
2023$46.74M−$114.33M−244.6%
2022$38.03M−$23.36M−61.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$30.25M$19.65M−$272.30M−$358.73M−1185.8%
2024$56.59M$39.90M−$92.79M−$72.81M−128.7%
2023$46.74M$31.06M−$105.43M−$114.33M−244.6%
2022$38.03M$27.24M−$50.63M−$23.36M−61.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCLX Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricSCLXDrug Manufacturers - General medianvs median
P/S ratio1.213.1362% below
Profit margin0.00%8.09%8.1 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Scilex Holding Company (SCLX) is capitalised at $38.09M on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 34 employees.

The most recent close on file for SCLX is $5.42, dated September 4, 2026. That is +$0.13 (+2.56%) against the previous close. Over the past 52 weeks the price has ranged from $2.62 to $21.34. The latest close sits 107.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $30.25M. That is −46.54% against the prior fiscal year, when revenue was $56.59M. The same year closed with a net loss of $358.73M. Profit margin runs at 0%. That is 8.1 percentage points below the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are −50.2.

Across the 4 fiscal years on file, revenue moves from $38.03M in 2022 to $30.25M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 7.42. The price-to-sales ratio is 1.21. On price-to-sales that is 61.52% below the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Beta against the wider market is reported at 1.72. Daily returns over the trailing 5 years annualize to a volatility of 113.78%. The trailing one-year price return is −57.33%. Measured over 5 years, that is −52.23% a year compounded.

Growth & Income

The record shows no dividend for SCLX.

The strongest complete calendar year on file is 2025 at −18.18%; the weakest is 2024 at −79.12%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −28.72% year to date.

Peer Comparison

Scilex Holding Company (SCLX) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Scilex Holding Company SCLX $38.09M —
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Scilex Holding Company has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Visit website →